3-chloro-5-(4-pyridinyl)pyridine-2-hydrazine | 79739-38-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-chloro-5-(4-pyridinyl)pyridine-2-hydrazine
• 英文别名: (3-Chloro-5-pyridin-4-ylpyridin-2-yl)hydrazine
• CAS: 79739-38-1
• 化学式: C₁₀H₉ClN₄
• 分子量: 220.661
• InChiKey: KPXJIGWEZYJUNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-chloro-5-(4-pyridinyl)pyridine-2-hydrazine 、 甲烷 在 aluminum nickel 作用下， 以 N-甲基乙酰胺 、 盐酸 、 乙醇 、 氢气 为溶剂， 生成 3-chloro-5-(4-pyridinyl)pyridin-2-amine dihydrochloride monohydrate
  参考文献：
  名称：

  5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their

  摘要：

  2-R.sub.3 RN-3-R.sub.1 R'N-5-PY-6-Q-吡啶类化合物（I）或其药用可接受的酸盐在制备1-或3-取代-1,3-二氢-5-Q-6-PY-2H-咪唑[4,5-b]吡啶-2-酮或-2-硫酮以及制备1-或3-取代-5-Q-6-PY-3H（或1H）-咪唑[4,5-b]吡啶的中间体中是有用的，其中R.sub.1、R.sub.3、R、R'、PY和Q的定义如下。还显示了制备I及其中使用的以下中间体的过程：2-卤代-3-硝基-5-PY-6-Q-吡啶类化合物（III）、2-R.sub.3 RN-3-硝基-5-PY-6-Q-吡啶类化合物（V）、2-卤代-5-PY-6-Q-吡啶类化合物（VII）、2-R.sub.3 RN-5-PY-6-Q-吡啶类化合物（VIII）和2-R.sub.3 RN-3-卤代-5-PY-6-Q-吡啶类化合物（IX）或其盐。II和VIII的某些实施例也可用作强心剂，并显示为心脏组合物的活性成分和增加心脏收缩力的方法。

  公开号：

  US04297360A1
• 作为产物：
  描述：

  2,3-Dichloro-5-pyridin-4-ylpyridine 生成 3-chloro-5-(4-pyridinyl)pyridine-2-hydrazine
  参考文献：
  名称：

  LESHER, G. Y.;OPALKA, C. J. ,, JR;PAGE, D. F.

  摘要：

  DOI：

文献信息

• Compositions and their preparation
  申请人：Sterling Drug Inc.

  公开号：US04276293A1

  公开（公告）日：1981-06-30

  2-R.sub.2 -3-R.sub.3 -6-PY-5-Q-3H-imidazo[4,5-b]pyridines (I) or 1-R.sub.1 -2-R.sub.2 -6-PY-5-Q-1H-imidazo[4,5-b]pyridines (IA) or pharmaceutically-acceptable acid-addition salts thereof, where Q and R.sub.2 are each hydrogen or lower-alkyl, R.sub.1 and R.sub.3 are each hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene having at least two carbon atoms between its connecting linkages and NB is di-(lower-alkyl)amino or 4-morpholinyl, at least one of R.sub.1 or R.sub.3 being hydrogen, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, which are useful as cardiotonics, are prepared by reacting 2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-pyridine (II) with a tri-(lower-alkyl) ortho-(lower-alkanoate). Also shown are: the use of I or IA or salts in cardiotonic compositions and a method for increasing cardiac contractility; and, the preparation of the intermediates II, as well as intermediates used to prepare II.

  2-R.sub.2 -3-R.sub.3 -6-PY-5-Q-3H-咪唑并[4,5-b]吡啶（I）或1-R.sub.1 -2-R.sub.2 -6-PY-5-Q-1H-咪唑并[4,5-b]吡啶（IA）或其药用可接受的酸盐，其中Q和R.sub.2分别为氢或低烷基，R.sub.1和R.sub.3分别为氢、低烷基、低羟基烷基、2,3-二羟基丙基、低烷氧基烷基或Y-NB，其中Y为至少在其连接链之间具有两个碳原子的低烷基，NB为二（低烷基）氨基或4-吗啉基，R.sub.1或R.sub.3中至少一个为氢，PY为4-或3-吡啶基或带有一个或两个低烷基取代基的4-或3-吡啶基，这些化合物可用作心力衰竭药物，通过将2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-吡啶（II）与三（低烷基）邻-(低烷酸酯)反应制备。还显示了：在心力衰竭药物组合物中使用I或IA或盐以及增加心脏收缩力的方法；以及用于制备II的中间体II的制备，以及用于制备II的中间体。
• 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and
  申请人：Sterling Drug Inc.

  公开号：US04294837A1

  公开（公告）日：1981-10-13

  1,3-Dihydro-1-R.sub.1 -3-R.sub.3 -6-PY-5-Q-2H-imidazo[4,5-b]pyridin-2-ones or -2-thiones or pharmaceutically-acceptable acid-addition salts thereof, which are useful as cardiotonic agents, where Q is hydrogen or lower-alkyl, R.sub.1 and R.sub.3 are each hydrogen, lower-alkyl, lower-hydroxyalkyl, 2,3-dihydroxypropyl, lower-alkoxyalkyl or Y-NB where Y is lower-alkylene and NB is di-(lower-alkyl)amino or 4-morpholinyl, at least one of R.sub.1 and R.sub.3 being hydrogen, and PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two substituents, are prepared by reacting a 2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-pyridine with urea or carbonyldiimidazole to produce said -2-one or with an alkali metal xanthate, thiourea or thiocarbonyldiimidazole to produce said -2-thione. Also shown and claimed are cardiotonic compositions and a method for increasing cardiac contractility using said cardiotonic agents. Also shown are processes for preparing said intermediate 2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-pyridines and other intermediates used in said processes.

  1,3-二氢-1-R.sub.1-3-R.sub.3-6-PY-5-Q-2H-咪唑并[4,5-b]吡啶-2-酮或-2-硫酮或其药用可接受的酸加合物盐，可用作心力衰竭药物，其中Q为氢或较低烷基，R.sub.1和R.sub.3分别为氢、较低烷基、较低羟基烷基、2,3-二羟基丙基、较低烷氧基烷基或Y-NB，其中Y为较低烷基烯和NB为二-(较低烷基)氨基或4-吗啉基，R.sub.1和R.sub.3中至少有一个为氢，PY为4-或3-吡啶基或带有一个或两个取代基的4-或3-吡啶基，通过将2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-吡啶与尿素或羰基二咪唑反应制备所述的-2-酮，或与碱金属黄原酸酯、硫脲或硫代羰基二咪唑反应制备所述的-2-硫酮。还显示并声称心力衰竭组合物和使用所述心力衰竭药物增加心脏收缩力的方法。还显示了制备所述中间体2-R.sub.3 NH-3-R.sub.1 NH-5-PY-6-Q-吡啶和所述过程中使用的其他中间体的方法。
• 5-(Pyridinyl)pyridine-2-hydrazines, their preparation and their
  申请人：Sterling Drug Inc.

  公开号：US04331672A1

  公开（公告）日：1982-05-25

  2-[R.sub.1 NHN(R)]-3-Q'-5-Py-6-Q-pyridines or pharmaceutically-acceptable acid-addition salts thereof are useful as cardiotonic agents, where Q is hydrogen or lower-alkyl, PY is 4- or 3-pyridinyl or 4- or 3-pyridinyl having one or two lower-alkyl substituents, Q' is hydrogen or halo, R is hydrogen, lower-alkyl or lower-hydroxyalkyl, and R.sub.1 is hydrogen or when R is other than hydrogen R.sub.1 is the same as R. These compounds are prepared by reacting a 2-halo-3-Q'-5-PY-6-Q-pyridine with R.sub.1 NHNHR where 2-halo is bromo or chloro. Also shown are: the use of said 2-[R.sub.1 NN(R)]-3-Q'-5-PY-6-Q-pyridines as cardiotonic agents; and, the intermediates, 2,3-dihalo-5-PY-6-Q-pyridines, and their preparation from 3-nitro-5-PY-6-Q-2(1H)-pyridinones.

  2-[R.sub.1 NHN(R)]-3-Q'-5-Py-6-Q-吡啶或其药学上可接受的酸盐是作为心脏强心剂有用的化合物，其中Q为氢或较低的烷基，PY为4-或3-吡啶基或具有一个或两个较低的烷基取代基的4-或3-吡啶基，Q'为氢或卤素，R为氢、较低的烷基或较低的羟基烷基，而R.sub.1为氢或当R不是氢时，R.sub.1与R相同。这些化合物是通过将2-卤代-3-Q'-5-PY-6-Q-吡啶与R.sub.1 NHNHR反应制备的，其中2-卤代为溴或氯。还显示了：所述2-[R.sub.1 NN(R)]-3-Q'-5-PY-6-Q-吡啶作为心脏强心剂的用途；以及中间体2,3-二卤代-5-PY-6-Q-吡啶和它们从3-硝基-5-PY-6-Q-2（1H）-吡啶酮的制备。
• US4276293A
  申请人：——

  公开号：US4276293A

  公开（公告）日：1981-06-30
• US4294837A
  申请人：——

  公开号：US4294837A

  公开（公告）日：1981-10-13